Clinical Trials List
Protocol NumberVedolizumab-5026
Not yet recruiting
2017-08-15 - 2020-05-31
Phase IV
Terminated1
-
Sponsor
-
Trial scale
-
Update
2026/03/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
350 participants
-
Global
0 participants
